Cell proliferation defects in KRAS mutant pancreatic cancer cells in response to CRAF inhibition occur without p-ERK attenuation [74] and may be attributed to the differences in the kinase-dependent and kinase-independent roles of CRAF in KRAS mutant lung cancer compared to KRAS mutant PDAC. This evidence concerns the gene RAF1 and lung carcinoma.